Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News


Treating Opioid Addiction with Ibogaine – Could This Be the Future?

It is no secret that psychedelics are showing promising results as a treatment for many health issues. Everywhere you turn there is a new study showing the benefits of psilocybin for depression or MDMA for PTSD. Perhaps most promising is the use of ibogaine to treat addiction and combat the opioid epidemic. Ibogaine is a…

Company Showcase

Segal Trials and Psychedelic Research in South Florida

After 24 years… and over 1,200 trials… across more than 75 therapies… Segal Trials is pushing into a new area of expertise—and helping pave the way for psychedelic clinical research. The company was recently selected as the first research site to conduct a Phase 2 study to test the efficacy and safety of LSD as…


Psychedelic Sector News – Weekly Extractions: August 5, 2022

It was another exciting week in the psychedelics industry. This week, Psychedelic Invest’s own Adam Tubero highlights the three biggest events of the week. The entire video can be found below. In addition, don’t forget that each Weekly Extraction is also listed underneath the video. Extraction #1: Aaron Rodgers Attributes His Success to Ayahuasca During…

MindMed Press

MindMed Board of Directors Approves Reverse Share Split

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of the reverse share split, there will be approximately 28.4 million shares…


Psychedelics Could Disrupt the $42 Billion a Year Rehab Industry

Many eager investors have been flocking to psychedelics with the “gold rush” mentality over the past few years. Another industry that has seen this pattern over the past decade is rehab. The burgeoning psychedelic treatment space has a lot of cross-over with addiction treatment and rehabilitation.  In 2020, drug and alcohol addiction treatment brought in…

MindMed Press

MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed’s management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11, 2022. Canaccord Genuity 42nd Annual Growth ConferenceFormat: In-person…

Company Showcase

Retreats and the Transformative Effects of Ketamine

Presented by What would it look like to create a profound, lasting transformation in your life? To completely rewire your brain to support growth and flexibility? To open yourself up to new awareness and insights you have never considered? To spark creativity and inspiration you have never imagined? Or to address and heal trauma from…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.